Abnormalities in the expression of CD55 and CD59 surface molecules on peripheral blood cells are not specific to paroxysmal nocturnal hemoglobinuria

Hematology

Volumn 14, Issue 1, 2009, Pages 33-37

  Ruiz Delgado, Guillermo J ^a,b   Vázquez Garza, Eduardo ^a   Méndez Ramírez, Nereida ^a   Gómez Almaguer, David ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

Author keywords

CD55 and CD59 surface molecules; Paroxysmal nocturnal hemoglobinuria

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;

ANTIGEN EXPRESSION; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; BLOOD CELL; CELL LINE; ERYTHROCYTE; GRANULOCYTE; HUMAN; LEUKOCYTE DISORDER; MAJOR CLINICAL STUDY; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEFICIENCY; PROTEIN FUNCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE; BIOSYNTHESIS; BLOOD; FLOW CYTOMETRY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIGENS, CD55; ANTIGENS, CD59; BLOOD PLATELETS; CELL LINE; FLOW CYTOMETRY; GRANULOCYTES; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 64949130812     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453309X385089     Document Type: Article

References (45)

1. Walport MJ. Complement. N Engl J Med 2001; 344: 1058-1066.
2. Welch TR. Complement in glomerulonephritis. Nat Genet 2002; 31: 333-334.
3. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence of antibody-and complement-mediated demyelination. Ann Neurol 1998; 43: 465-471.
4. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv Immunol 1996; 61: 201-283.
5. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertase of the complement system. J Immunol 1982; 129: 184-189.
6. Seya T, Hara T, Iwata K, et al. Purification and functional properties of soluble forms of membrane cofactor protein (MCP, CD46) of complement: Identification of forms increased in cancer patients' sera. Int Immunol 1995; 7: 727-736.
7. Davies A, Simmons DL, Hale G, et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989; 170: 637-654.
8. Hebert LA. Clearance of immune complexes from the circulation of man and other primates. Am J Kidney Dis 1987; 17: 352-361.
9. Nicholson-Weller A, Wang CE. Structure and function of decay accelerating factor CD55. J Lab Clin Med 1994; 123: 485-491.
10. Finberg RW, White W, Nicholson-Weller A. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol 1992; 149: 2055-2060.
11. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 1983; 80: 5066-5070.
12. Pangburg MK, Schreiber RD, Muller-Eberhard HJ. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1983; 80: 5430-5434.
13. Telen MJ, Green AM. The Inab phenotype: Characterization of the membrane protein and complement regulatory defect. Blood 1989; 74: 437-441.
14. Clarkson NA, Kaufman R, Lublin DM, et al. Characterization of the echovirus 7 receptor: Domains of CD55 critical for virus binding. J Virol 1995; 69: 5497-5501.
15. Shafren DR, Bates RC, Agrez MV, Herd RL, Burns GF, Barry RD. Coxsackie viruses B1, B3 and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 1995; 69: 3873-3877.
16. Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Saifuddin M. Host-cell derived complement control proteins CD55 and CD59 are incorporated in to the virions of two unrelated enveloped viruses. Human T Cell leukemia/lymphoma virus type I (HTLV-1) and human cytomegalovirus (HCMV). J Immunol 1995; 155: 4376-4381.
17. Kieffer B, Driscoll PC, Campbell ID, Willis AC, van der Merwe PA, Davis SJ. Three-dimensional solution structure of the extracellular region of the complement regulatory protein CD59, a new cell surface protein domain related to snake venom neurotoxins. Biochemistry 1994; 33: 4471-4482.
18. Meri S, Waldman H, Lachmann PJ. Distribution of protecting (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 1991; 65: 532-537.
19. Lachmann PJ. The control of homologous lysis. Immunol Today 1991; 12: 312-315.
20. Bessler M, Hillmen P. Somatic mutation and clonal selection in the pathogenesis and in the control of paroxysmal nocturnal hemoglobinuria. Semin Hematol 1998; 35: 149-167.
21. Brodsky RA, Mukhina GL, Li S. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol 2000; 114: 459-466.
22. Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-1258.
23. Richards S, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal noctural hemoglobinuria. Cytometry 2000; 42: 223-233.
24. Richaud-Patin Y, Pérez-Romano B, Carrillo-Maravilla E, et al. Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus. Immunol Lett 2003; 88: 95-99.
25. Douglas B, Cines MD, Victor S, Blanchette MB, Chir B. Immune thrombocytopenic purpura. New Engl J Med 2002; 346: 995-1008.
26. Fabris F, Steffan A, Cordiano I, et al. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol 1994; 53: 232-236.
27. How M, Stockelberg D, Kutti J, Wadenvik H. Immunoglobulins targeting both GPIIb/IIIa and GP Ib/IX in chronic idiopathic thrombocytopenic purpura (ITP): Evidence for at least two different IgG antibodies. Br J Haematol 1997; 98: 64-67.
28. How M, Stockelberg D, Kutti J, Wadenvik H. Fab-mediated binding of glycoprotein Ib/IX and IIb/IIIa specific antibodies in chronic idiopathic thrombocytopenic purpura. Br J Haematol 1995; 91: 944-950.
29. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J, ITP Study Group. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76: 205-213.
30. Ruiz-Argüelles A, León-Lloret M, Richaud-Patin Y, Llorente L, Ruiz-Argüelles GJ. Acquired deficiency of CD55 and CD59 in autoimmune hemocytopenias. In: Veskler BA. (ed) Leading edge immunology research. New York: Nova Publishers Inc., 2006; 79-94.
31. Rivero SJ, Diaz-Jouanen E, Alarcon-Segovia D. Lymphopenia in systemic lupus erythematosus. Arthritis Rheum 1978; 21: 295-305
32. Drenkard C, Villa AR, Garcia-Padilla C, Perez-Vazquez ME, Alarcon-Segovia D. Remission of systemic lupus erythematosus. Medicine (Baltimore) 1996; 75: 88-98.
33. Winfield JB. Antilymphocyte autoantibodies. In: Wallace DJ, Hahn BH. (eds) Dubois' lupus erythematosus. Baltimore, MD: Williams and Wilkins, 1997; 505-515.
34. van Beek J, van Meurs M, 't Hart VA, et al. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation. J Immunol 2005; 174: 2353-2365
35. Ruiz-Arguelles GJ. Hipoplasias y displasias medulares. In: Ruiz-Arguelles GJ. (ed) Fundamentos de Hematología, 3rd edition. México: Editorial Médica Panamericana, 2003; 185-202.
36. Young, NS. Acquired aplastic anemia. In: Schechter GP, Berliner N, Telen MJ. (eds) Hematology 2000. Washington, DC: The American Society of Hematology Education Program Book, 2000; 18-38.
37. Delgado-Lamas JL, López-Karpovitch X, Marín-López A, et al. Low doses of high potency antithymocite globulin (ATG) in severe aplastic anemia: Experience with theMexican ATG. Acta Haematol 1989; 81: 70-74.
38. Ruiz-Arguelles GJ, Gomez Rangel, D. Long term results of the immunosuppressive treatment of patients with severe acquired aplastic anemia: A single institution study. Acta Haematologica 2003; 110: 184-187.
39. Sánchez-Medal L, Ruiz-Reyes G. Geographical variation in blood diseases: Latin America. In: Wheatherall DJ, Ledingham JGG, Warrell DA. (eds) Oxford's textbook of medicine. Oxford: Oxford Medical, 1987; 268-70.
40. Romero F. Incidencia de la anemia aplástica en Iberoamérica. In: López-Borrasca A, et al. (eds) Enciclopedia Iberoamericana de Hematología. Salamanca: Ediciones Universidad de Salamanca, 1992; 659-661.
41. Benítez-Aranda H, Velez-Ruelas MA, Díaz-Cardenas S, et al. Incidence of aplastic anemia in a defined subpopulation from Mexico City. Hematology 2002; 7: 229-232.
42. Gongora-Biachi R, Gonzalez-Martinez P, Gonzalez-Llaven J, et al. Clinical spectrum and prognostic factors in paroxysmal nocturnal hemoglobinuria in Mexico. Rev Invest Clin 1994; 46(suppl 1): 187.
43. Gongora-Biachi R, Gonzalez-Martinez P, Sosa-Muñoz J, et al. Natural history of paroxysmal nocturnal Hemoglobinuria in adolescents, adults, and children: The Mexican experience. Sangre (Barc) 1997; 42: 171-177.
44. Ruiz-Argüelles GJ, Ramírez Cisneros FJ, Ruiz-Argüelles A, et al. Deficiencia de proteínas de superficie ancladas por glucosil-fosfatidil-inositol en celulas de pacientes mestizos mexicanos con hipoplasia medular. Rev Invest Clín Méx 1999; 51: 5-9.
45. Evans RS, Takahashi K, Duane RT, Payne R. Primary thrombocytopenic purpura and acquired hemolytic anemia: Evidence for a common etiology. AMA Arch Intern Med 1951; 1: 48-65.